Literature DB >> 30408197

Canal wall up surgery with mastoid and epitympanic obliteration in acquired cholesteatoma.

Catharine A Hellingman1, Simon Geerse1, Maarten J F de Wolf1, Fenna A Ebbens1, Erik van Spronsen1.   

Abstract

OBJECTIVES/HYPOTHESIS: The objective of this study was to evaluate surgical outcome and residual and recurrence rates of canal wall up (CWU) surgery with obliteration of the mastoid and epitympanum. STUDY
DESIGN: Retrospective cohort study in a tertiary referral center.
METHODS: Patients with (sequelae of) acquired cholesteatoma treated with primary or revision CWU surgery with obliteration of the epitympanum and mastoid were identified retrospectively from 2010 to 2014. Obliteration was performed with cartilage chips or a periosteal midtemporal flap in combination with bone pâté and/or hydroxyapatite. Patients were followed up with micro-otoscopy and magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI).
RESULTS: Ninety-nine ears in 96 patients were managed with obliteration of the epitympanum and mastoid following CWU surgery. Mean postoperative follow-up was 39.6 (standard deviation [SD] = 16.3). Mean follow-up until the last MRI-DWI was 29.7 months (SD = 16.0). In total, 74 ears in 72 adult patients (mean age = 46.8 years) were operated and 25 ears in 24 pediatric patients (mean age = 12.8 years). The overall recurrence rate was 7.1%, and the residual rate was 7.1%. In comparison, before the introduction of obliteration, the residual rate in our clinic was 24.4% and the recurrence rate 39.7%. After CWU surgery with obliteration, recurrence in pediatric patients (16.0%) was more frequent than in adults (4.1%). Although this difference was not statistically significant, a trend was observed (P = .066).
CONCLUSIONS: Obliteration of the epitympanum and mastoid is a reliable and safe technique following CWU surgery for cholesteatoma, resulting in low residual and recurrence rates. LEVEL OF EVIDENCE: 4 Laryngoscope, 129:981-985, 2019.
© 2018 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Cholesteatoma; canal wall up; hearing outcome; mastoid surgery; obliteration; recurrence; residual disease

Mesh:

Year:  2018        PMID: 30408197     DOI: 10.1002/lary.27588

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Cholesteatoma surgery in the pediatric population: remaining challenges in the era of mastoid obliteration.

Authors:  Victor J Kroon; Steven W Mes; Pepijn A Borggreven; Rick van de Langenberg; David R Colnot; Jasper J Quak
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-10-08       Impact factor: 3.236

2.  Mastoid obliteration with hydroxyapatite vs. bone pâté in mastoidectomy surgery performed on patients with cholesteatoma and chronic suppurative otitis media: a retrospective analysis.

Authors:  Jantine J Lindeboom; P M W van Kempen; J Buwalda; B O Westerlaken; D A van Zuijlen; S J H Bom; F B van der Beek
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-09-29       Impact factor: 3.236

3.  Mid-term outcomes of mastoid obliteration with biological hydroxyapatite versus bioglass: a radiological and clinical study.

Authors:  Sonia Sahli-Vivicorsi; Zarrin Alavi; William Bran; Romain Cadieu; Philippe Meriot; Jean-Christophe Leclere; Rémi Marianowski
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-17       Impact factor: 3.236

4.  Post-operative healing and long-term stability after mastoid cavity reconstruction using the middle temporal artery and inferior musculoperiosteal flaps.

Authors:  Arthur Dexian Tan; Jia Hui Ng; David Yong-Ming Low; Heng Wai Yuen
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-15       Impact factor: 2.503

5.  Long-term follow-up of applying autologous bone grafts for reconstructing tympanomastoid defects in functional cholesteatoma surgery.

Authors:  Wei-Che Lan; Ching-Yuan Wang; Ming-Hsui Tsai; Chia-Der Lin
Journal:  PeerJ       Date:  2021-11-23       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.